Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study for the Safety and Expression of Dystrophin in Skeletal Muscle After SPOT-03 Administration in Duchenne Muscular Dystrophy (DMD) Patients

NCT07188012 is registered in ClinicalTrials.gov with Shanghai Siponuoyin Biotechnology Co Ltd as lead sponsor.

NCT NCT07188012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07188012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study for the Safety and Expression of Dystrophin in Skeletal Muscle After SPOT-03 Administration in Duchenne Muscular Dystrophy (DMD) Patients
Lead sponsor
Shanghai Siponuoyin Biotechnology Co Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
August 6, 2025
Completion date
December 31, 2026
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy (dmd)